# A Dose-optimization Study of Aldurazyme® (Laronidase) in Patients With Mucopolysaccharidosis I (MPS I) Disease

> **NCT00144781** · PHASE4 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 34 (actual)

## Conditions studied

- Mucopolysaccharidosis I
- Hurler's Syndrome
- Hurler-Scheie Syndrome
- Scheie Syndrome

## Interventions

- **BIOLOGICAL:** Aldurazyme (Recombinant Human Alpha-L-Iduronidase)
- **BIOLOGICAL:** Aldurazyme (Recombinant Human Alpha-L-Iduronidase)
- **BIOLOGICAL:** Aldurazyme (Recombinant Human Alpha-L-Iduronidase)
- **BIOLOGICAL:** Aldurazyme (Recombinant Human Alpha-L-Iduronidase)

## Key facts

- **NCT ID:** NCT00144781
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-12
- **Primary completion:** 2006-01
- **Final completion:** 2006-01
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2015-04-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00144781

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00144781, "A Dose-optimization Study of Aldurazyme® (Laronidase) in Patients With Mucopolysaccharidosis I (MPS I) Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00144781. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*